Hungry bone syndrome in delay diagnosed primary hyperparathyroidism with fi brocystic osteitis: A case report

Fibrocystic osteitis is a rare but severe primary hyperparathyroidism (PHPT) complication. We describe a 66-year-old female presented with fi brocystic osteitis and nephrocalcinosis with eGFR reduction to CKD stage 4 due to primary hyperparathyroidism. Delayed diagnosis of long-term hypercalcemia, high parathyroid hormone level, unsubstituted 25(OH)D defi ciency, and the use of bisphosphonates in high doses caused development of «hungry bones» syndrome in early postoperative period. Severe hypocalcemia required prescription of active and native vitamin D metabolites, oral calcium supplements as well as intravenous calcium. Delay in diagnosis of PHPT with fi brocystic osteitis formation led to lower well-being, reduced quality of life and also provoked sever postoperative hypocalcemia («hungry bone» syndrome).

1. Melton LJ 3rd. The epidemiology of primary hyperparathy-roidism in North America. J Bone Miner Res. 2002;17 Suppl 2:N12-7. PMID: 12412772.

2. Yanevskaya LG, Karonova T, Sleptsov IV, Boriskova ME, Bakhtiyarova AR, et al. Clinical phenotypes of primary hyperparathyroidism in hospitalized patients who underwent parathyroidectomy. Endocr Connect. 2021;10(2):248-255. DOI: 10.1530/EC-20-0515.

3. Hamidi S, Mottard S, Berthiaume MJ, Doyon J, Bégin MJ, Bondaz L. Brown tumor of the iliac crest initially misdiagnosed as a giant cell tumor of the bone. Endocrinol Diabetes Metab Case Rep. 2020;2020:20-0029. DOI: 10.1530/EDM-20-0029. Epub ahead of print.

4. Witteveen JE, van Th iel S, Romijn JA, Hamdy NA. Hungry bone syndrome: still a challenge in the post-operative man-agement of primary hyperparathyroidism: a systematic re-view of the literature. Eur J Endocrinol. 2013;168(3):R45-53. DOI: 10.1530/EJE-12-0528.

5. Ferraz-de-Souza B. Th e evolution of primary hyperpara-thyroidism. Arch Endocrinol Metab. 2015;59(5):381-2. DOI: 10.1590/2359-3997000000124.

6. Naji Rad S., Deluxe L. Osteitis Fibrosa Cystica. StatPearls. Treasure Island (FL): StatPearls Publishing.; 2021. 6. Naji Rad S, Deluxe L. Osteitis Fibrosa Cystica. StatPearls.

7. Makras P, Anastasilakis AD. Bone disease in primary hyper-parathyroidism. Metabolism. 2018;80:57-65. DOI: 10.1016/j.metabol.2017.10.003.

8. Bandeira F, Cusano NE, Silva BC, Cassibba S, Almeida CB, et al. Bone disease in primary hyperparathyroidism. Arq Bras Endocrinol Metabol. 2014;58(5):553-61. DOI: 10.1590/0004-2730000003381.

9. Bilezikian JP, Cusano NE, Khan AA, Liu JM, Marcocci C, Bandeira F. Primary hyperparathyroidism. Nat Rev Dis Primers. 2016;2:16033. DOI: 10.1038/nrdp.2016.33.

10. Mokrysheva N.G., Eremkina A.K., Mirnaya S.S., Krupinova J.A., Voronkova I.A., et al.. Th e clinical practice guidelines for pri-mary hyperparathyroidism, short version. Problems of Endocri-nology. 2021;67(4):94-124. (In Russ.) DOI: 10.14341/probl12801

11. Wilhelm SM, Wang TS, Ruan DT, Lee JA, Asa SL, et al. Th e Amer-ican Association of Endocrine Surgeons Guidelines for Defi ni-tive Management of Primary Hyperparathyroidism. JAMA Surg. 2016;151(10):959-968. DOI: 10.1001/jamasurg.2016.2310.

12. Bilezikian JP. Primary Hyperparathyroidism. J Clin Endocrinol Metab. 2018;103(11):3993-4004. DOI: 10.1210/jc.2018-01225.

13. Misiorowski W, Bilezikian JP. Osteitis Fibrosa Cystica. JBMR Plus. 2020;4(9):e10403. DOI: 10.1002/jbm4.10403.